Drug
Cationic Liposome-Encapsulated Paclitaxel clinical trials
How studies write it
Studies that test it under each name
Name
- EndoTAG-1
- 5
Studies by the year they started
6 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 2 |
| 2011 | 1 |
| 2016 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 1
MediGene (3) · SynCore Biotechnology Co., Ltd. (2) · Jules Bordet Institute (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Antimitotic Agents source
Studies
Open first, then newest update. How each study uses Cationic Liposome-Encapsulated Paclitaxel is read from its arms, and is right about nine times in ten.
Testing it · 6
- EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOXCompletedPhase 3SynCore Biotechnology Co., Ltd.NCT03126435Written as EndoTAG-1
- A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast CancerSuspendedPhase 3SynCore Biotechnology Co., Ltd.NCT03002103Written as EndoTAG-1
- Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast CancerCompletedPhase 2Jules Bordet InstituteNCT01537536Written as EndoTAG-1
- EndoTAG-1 in Triple Receptor Negative Breast Cancer PatientsCompletedPhase 2MediGeneNCT00448305Written as EndoTAG-1 + paclitaxel
- A Trial Evaluating the Pharmacokinetics and Mode of Action of EndoTAG®-1 in Tumor Patients With Hepatic MetastasesCompletedPhase 2MediGeneNCT00542048Written as EndoTAG®-1
- EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the PancreasCompletedPhase 2MediGeneNCT00377936Written as EndoTAG-1 and Gemcitabine